0001193125-14-439080.txt : 201412100001193125-14-439080.hdr.sgml
: 2014121020141210171233ACCESSION
NUMBER:0001193125-14-439080CONFORMED SUBMISSION TYPE:SC TO-CPUBLIC
DOCUMENT COUNT:51FILED AS OF DATE:20141210DATE AS OF
CHANGE:20141210GROUP MEMBERS:BIOMARIN FALCONS B.V.
SUBJECT COMPANY:
COMPANY DATA:COMPANY CONFORMED NAME:Prosensa Holding N.V.CENTRAL
INDEX KEY:0001574111STANDARD INDUSTRIAL
CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS
NUMBER:000000000STATE OF INCORPORATION:P7FISCAL YEAR END:1231
FILING VALUES:FORM TYPE:SC TO-CSEC ACT:1934 ActSEC FILE
NUMBER:005-87624FILM NUMBER:141278713
BUSINESS ADDRESS:STREET 1:J.H. OORTWEG 21CITY:2133 CH
LEIDENSTATE:P7ZIP:00000BUSINESS PHONE:31 0 713320100
MAIL ADDRESS:STREET 1:J.H. OORTWEG 21CITY:2133 CH
LEIDENSTATE:P7ZIP:00000
FORMER COMPANY:FORMER CONFORMED NAME:Prosensa Holding B.V.DATE
OF NAME CHANGE:20130410
FILED BY:
COMPANY DATA:COMPANY CONFORMED NAME:BIOMARIN PHARMACEUTICAL
INCCENTRAL INDEX KEY:0001048477STANDARD INDUSTRIAL
CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS
NUMBER:680397820STATE OF INCORPORATION:DEFISCAL YEAR END:1231
FILING VALUES:FORM TYPE:SC TO-C
BUSINESS ADDRESS:STREET 1:105 DIGITAL
DRIVECITY:NOVATOSTATE:CAZIP:94949BUSINESS PHONE:4155066700
MAIL ADDRESS:STREET 1:105 DIGITAL
DRIVECITY:NOVATOSTATE:CAZIP:94949
SC TO-C1d836571dsctoc.htmSC TO-C
SC TO-C
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
(RULE 14d100)
Tender Offer Statement Pursuant to Section14(d)(1) or
13(e)(1)
of the Securities Exchange Act of 1934
ProsensaHolding N.V.
(Name of Subject Company)
BioMarin Falcons B.V.
(Offeror)
BioMarinPharmaceutical Inc.
(Parent of Offeror)
(Names of Filing Persons)
ORDINARYSHARES, PAR VALUE 0.01 PER SHARE
(Title of Class of Securities)
N71546100
(Cusip Numberof Class of Securities)
G. Eric Davis
Senior Vice President, General Counsel
BioMarin Pharmaceutical Inc.
770 Lindaro Street
SanRafael, California 94901
(415) 506-6700
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications on Behalf of Filing
Persons)
With a copy to:
Kevin Espinola
JonesDay
3161 Michelson Dr., Suite 800
Irvine, California 92612
(949) 851-3939
CALCULATIONOF FILING FEE
Transaction Valuation*Amount of Filing Fee*
N/A*N/A*
*A filing fee is not required in connection with this filing as
it relates solely to preliminary communications made before the
commencement of the tender offer.
Check the box if any part of the fee is offset as provided by
Rule 0-11(a)(2) and identify the filing with which the offsetting
fee was previously paid. Identify the previous filing by
registration statement number, orthe Form or Schedule and the date
of its filing.
Amount Previously Paid: n/aFiling Party: n/a
Form of Registration No.: n/aDate Filed: n/a
xCheck the box if the filing relates solely to preliminary
communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions
to which the statement relates:
xThird-party tender offer subject to Rule 14d-1.
Issuer tender offer subject to Rule 13e-4.
Going-private transaction subject to Rule 13e-3.
Amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a finalamendment
reporting the results of the tender offer.
If applicable, check theappropriate box(es) below to designate
the appropriate rule provision(s) relied upon:
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
This filing relates solely to preliminary communications made
before the commencement of a tender offer (theOffer) by BioMarin
Falcons B.V., (Buyer) a private company with limited liability
organized under the laws of The Netherlands and an indirect wholly
owned subsidiary of BioMarin Pharmaceutical Inc., a
Delawarecorporation (BioMarin or the Company), to purchase all of
the issued and outstanding ordinary shares, par value 0.01per share
(the Shares), of Prosensa Holding N.V., a publiclimited liability
company organized under the laws of The Netherlands (Prosensa), at
a purchase price of $17.75 per Share, net to the seller in cash,
plus one non-transferrable contingent value right per Share, which
representsthe contractual right to receive a cash payment of up to
$4.14 per Share upon the achievement of certain product approval
milestones, in each case, without interest thereon and less any
applicable withholding taxes, upon the terms and subject to
theconditions contained in the Purchase Agreement, dated as of
November23, 2014, by and among Buyer, BioMarin and Prosensa.
ADDITIONAL INFORMATION
The Offer described in this communication and related exhibits
has not yet commenced, and this communication and related exhibits
is neither an offerto purchase nor a solicitation of an offer to
sell any ordinary shares of Prosensa or any other securities. On
the commencement date of the Offer, a tender offer statement on
Schedule TO, including an offer to purchase, a letter of
transmittal andrelated documents, will be filed with the United
States Securities and Exchange Commission (the SEC). Thereafter,
Prosensa will file a solicitation/recommendation statement on
Schedule 14D-9 with the SEC. The offer to purchaseordinary shares
of Prosensa will only be made pursuant to the offer to purchase,
the letter of transmittal and related documents filed as a part of
the Schedule TO.
INVESTORS AND SECURITY HOLDERS OF PROSENSA ARE URGED TO READ
BOTH THE SCHEDULE TO (AND THE INCLUDED OFFER TO PURCHASE) AND THE
SOLICITATION/RECOMMENDATIONSTATEMENT, AS THEY MAY BE AMENDED FROM
TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN
THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO
THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT THETERMS OF THE OFFER, THE PROPOSED TRANSACTIONS AND THE
PARTIES THERETO.
The tender offer statement will be filed with the SEC by
BioMarin and Buyer,and the solicitation/recommendation statement
will be filed with the SEC by Prosensa. Investors and security
holders may obtain a free copy of these statements (when available)
and other documents filed with the SEC at the website maintained by
theSEC at www.sec.gov or by directing such requests to the
Information Agent for the tender offer that will be named in the
tender offer statement on Schedule TO.
Cautionary Note Regarding Forward-Looking Statements
Anystatements contained in this document that are not historical
facts are forward-looking statements as defined in the U.S. Private
Securities Litigation Reform Act of 1995. Words such as anticipate,
believe,estimate, expect, forecast, intend, may, plan, project,
predict, should and will and similar expressions as they relate
tothe Company, Buyer or Prosensa are intended to identify such
forward-looking statements. These forward-looking statements
involve risks and uncertainties concerning the parties ability to
initiate the tender offer, close the transaction,terminate the
Purchase Agreement, the expected closing date of the transaction,
the anticipated benefits and synergies of the proposed transaction,
anticipated future combined operations, products and services.
Actual events or results may differmaterially from those described
in this document due to a number of risks and uncertainties. These
potential risks and uncertainties include,
among others, the outcome of regulatory reviews of the proposed
transaction, the ability of the parties to complete the
transaction, and other risks detailed in the Companys andProsensas
SEC filings, including those discussed in the Companys Annual
Report on Form 10-K for the year ended December31, 2013 and in any
subsequent periodic reports on Form 10-Q and Form 8-K and Prosesas
Annual Report onForm 20-F for the year ended December31, 2013 and
in any subsequent reports on Form 6-K, each of which is on file
with the SEC and available at the SECs website at www.sec.gov. The
Company is not obligated to update these forward-lookingstatements
to reflect events or circumstances after the date of this document.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of their dates.
EXHIBIT INDEX
Exhibit99.1Slides Presented at Investor Conference, dated
December10, 2014
EX-99.12d836571dex991.htmEX-99.1
EX-99.1
Exhibit 99.1
WELCOME BIOMARIN ANALYST AND INVESTOR DAY 2014 Jean-Jacques
Bienaime Chief Executive Officer Hank Fuchs Chief Medical
Officer
ANALYST DAY 2014 Safe Harbor Statement This non-confidential
presentation contains forward-looking statements about the business
prospects of BioMarin Pharmaceutical Inc.,including potential
future products in different areas of therapeutic research and
development. Results may differ materially depending on the
progress of BioMarins product programs, actions of regulatory
authorities, availability of capital,future actions in the
pharmaceutical market and developments by competitors, and those
factors detailed in BioMarins filings with the Securities and
Exchange Commission such as 10-Q, 10-K and 8-K reports. 2
ANALYST DAY 2014 Additional Information The offer by BioMarin to
purchase ordinary shares of Prosensa Holding N.V. (Prosensa)
contemplated by the Purchase Agreement, datedNovember 23, 2014,
between BioMarin, Prosensa and BioMarin Falcons B.V. (the Offer)
has not yet commenced. This communication is neither an offer to
purchase nor a solicitation of an offer to sell any ordinary shares
of Prosensa or anyother securities. On the commencement date of the
Offer, a tender offer statement on Schedule TO, including an offer
to purchase, a letter of transmittal and related documents, will be
filed with the United States Securities and Exchange Commission(the
SEC). Thereafter, Prosensa will file a solicitation/recommendation
statement on Schedule 14D-9 with the SEC. The offer to purchase
ordinary shares of Prosensa will only be made pursuant to the offer
to purchase, the letter oftransmittal and related documents filed
as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS OF
PROSENSA ARE URGED TO READ BOTH THE SCHEDULE TO (AND THE INCLUDED
OFFER TO PURCHASE) AND THE SOLICITATION/ RECOMMENDATION STATEMENT,
AS THEY MAYBE AMENDED FROM TIME TO TIME, AND OTHER RELEVANT
DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY
MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TERMS OF THE OFFER,THE
PROPOSED TRANSACTIONS AND THE PARTIES THERETO. The tender offer
statement will be filed with the SEC by BioMarin and the
solicitation/recommendation statement will be filed with the SEC by
Prosensa. Investors and security holders may obtain afree copy of
these statements (when available) and other documents filed with
the SEC at the website maintained by the SEC at www.sec.gov or by
directing such requests to the information agent for the tender
offer that will be named in the tenderoffer statement on Schedule
TO. 3
ANALYST DAY 2014 2014: BioMarins Most Productive Year to Date
2015 will be more productive 5 Marketed Products to Generate over
$700M in 2014 Revenues Most Diverse Product Pipelinein Orphan-drug
Industry 5 Potential Products Currently in the Clinic; 8 in 2015*
Vimizim to Generate ~$100M in First Four Quarters of Sales Prosensa
Acquisition Could Drive Significant Near-term Upside * 12 including
drisapersen and other clinicalcandidates from Prosensa acquisition
4
ANALYST DAY 2014 Prosensa Acquisition Highlights Great strategic
fit and value creator for BioMarin Drisapersen has a large body of
clinical data that could support early regulatoryapproval Leverages
BioMarins extensive experience getting orphan drugs approved DMD is
one of the largest monogenetic disorders (approx. 75,000 WW)
Leverages our global commercial infrastructure and leadership in
orphan disease market Addswhat could be our largest product to a
well diversified product portfolio With early approvals, accretive
to operating and GAAP earnings in 2017 A potentially transformative
investment that is risk managed
ANALYST DAY 2014 Why Prosensa? First to file in the U.S. for the
treatment of Duchenne muscular dystrophy Our belief that the
totality of drisapersen data combined with the significantunmet
medical need of this patient population provide a path to early
approvals Largest data set in DMD comprising three
placebo-controlled studies and two long-term open label studies,
treating over 300 patients New Drug Application (NDA)
withBreakthrough Therapy designation currently under rolling review
based on existing data; complete NDA submission expected 1Q15; MAA
in EMA expected 2015 In-line with FDA guidance, two confirmatory
post-approval studies to support accelerated approvalplanned to
begin 1H15 Issued U.S. patents through 2023; EU through 2021;
potential for extensions Low dose that supports sub-cutaneous route
of administration Anticipated low COGS and available manufacturing
capacity to meet market demand
ANALYST DAY 2014 Drisapersen: Timeline of Regulatory Events 4Q14
NDA rolling submission commenced with FDA 1Q15 anticipated
completion of NDA submission with FDA 2Q15 expected MAAapplication
for drisapersen with EMA 1H15 initiation of two confirmatory
studies to support potential accelerated approval for
drisapersen
ANALYST DAY 2014 History of Strong Revenue Growth Core
Commercial Products Expected to Continue Growing VIMIZIM Naglazyme
Kuvan Aldurazyme + Other $26 2005 $84 2006 $122 2007 $297 2008$325
2009 $376 2010 $441 2011 $501 2012 $549 2013 $700+ $65- $70 $305-
$320 $190- $200 2014 (revenues in millions) Outlook 8
ANALYST DAY 2014 Whats New Today? Drisapersen Potential
near-term registration opportunity in large market with unmet need
Seamless fit within BioMarins clinical, regulatoryand commercial
expertise BMN 111 for Achondroplasia First 3 cohorts enrolled
Leveraging the natural history study to inform our understanding of
our patients and analytic approaches BMN 190 for CLN2, Late
Infantile Form of Batten Disease Enrollmentcompletion imminent
Current study exhibiting excellent safety profile to date BMN 270
for Hemophilia A Launching Phase 1 study 1H15 on track two years
after licensing Expanded pre-clinical proof of concept to include
real world(clotting) assays
ANALYST DAY 2014 Whats New Today? PEG PAL for PKU Phe lowering
in patients from enriched study at 26 weeks is robust at ~60%
Enhanced strategies in place to facilitatecommercialization Pivotal
data now expected 1Q16 BMN 701 for Late-onset Pompe Disease
Improved manufacturing process with better purity, potency and COGS
Modifying program to leverage to be commercialized process Proof of
concept in 20patients of switch study; enrollment 1Q15/results 4Q15
Pivotal study resumes 4Q15 Talazoparib for mBRCA BC Enrolling more
trials, including talazoparib in combination, neoadjuvant, etc. BMN
250 for MPS IIIB (Sanfilippo B syndrome) Launching naturalhistory
study with patient accrual expected 2015 Phase 1 study in MPS IIIB
patients 2H15
ANALYST DAY 2014 Agenda and Welcome External Speakers Cary O.
Harding, M.D., F.A.C.M.G. Professor of Molecular and Medical
Genetics and Pediatrics at Oregon Health & ScienceUniversity
Medical Director of the OHSU Biochemical Genetics Laboratory
Alfried Kohlschutter, M.D. Expert in NCL disorders (Neuronal Ceroid
Lipofuscinoses, Batten disease) Specialty Clinic for Degenerative
Brain Disorders in Children andAdolescents, associated with the
Department of Pediatrics, University Medical Center in Hamburg,
Germany Cathleen Raggio, M.D. Attending Orthopedic Surgeon,
Co-Director, The Kathryn O. and Alan C. Greenberg Center for
Skeletal Dysplasias at Hospitalfor Special Surgery, New York Craig
McDonald, M.D. Professor and Chair, Department of Physical Medicine
& Rehabilitation, Center for Healthcare Policy and Research
U.C. Davis Childrens Hospital Expert in the clinical management
andrehabilitation of neuromuscular diseases including muscular
dystrophies and the development of novel outcome measures for
clinical trials Glenn Pierce, M.D., Ph.D. Expert in the field of
hemophilia with more than 20 years of experience Previouslyserved
as the Chief Medical Officer and Senior Vice President of Biogen
Idec Hemophilia Therapeutic Area and senior vice president of
Hematology, Cell and Gene Therapies at Biogen Idec Inc. 11
PKU PROGRAM OVERVIEW FOCUS ON PEG PAL BIOMARIN ANALYST AND
INVESTOR DAY 2014 Wolfgang Dummer, M.D., Ph.D., Vice President,
Clinical Development BioMarin
Drisapersen: an overview of the clinical program in Duchenne
muscular dystrophy
Craig McDonald, MD Professor and Chair Physical Medicine&
Rehabilitation Professor of Pediatrics
Disclosures
Consulting work on Duchenne musculardystrophy clinical trials
for
PTC Therapeutics
Sarepta
Prosensa
Pfizer
Eli Lilly
Halo Therapeutics
Bristol MyersSquib
Novartis
Italfarmaco
Mitokyne
Cardero Therapeutics
Site investigator for phase 3 trials for ataluren and eteplirsen
Site investigator and study PI for DEMAND V study of drisapersen
Site investigator for drisapersen extension trial
Introduction
Duchenne muscular dystrophy (DMD) isa severely debilitating and
ultimately fatal childhood disease
Affects 1 in 35005000 newborn boys1,2
Characterized by a progressive decrease in muscle function3
leading to loss of ambulation, respiratory failureand
cardiomyopathy Caused by mutations in the dystrophin gene,
resulting in disruption of the open-reading frame, dystrophin
deficiency and muscle fibre degeneration4
Exon skipping:
A therapeutic strategy forrestoring partial functional
dystrophin expression
Aims to convert the more severe DMD into a milder Beckermuscular
dystrophy (BMD) phenotype
Drisapersen:
A 2-O-methyl-phosphorothioate antisense oligonucleotide that
induces skipping of exon 51 in the dystrophin pre-mRNA
Can be used to correct mutations occurring in approximately 13%
of boys with DMD5
1. Ellis JA, et al. Neuromuscul Disord 2013;23:6829. 2. Mendell
JR, et al. Muscle& Nerve2013;48:216. 3. Emery AE. Duchenne
Muscular Dystrophy (3rd ed). Oxford University Press; Oxford, UK:
2003. 4. Aartsma-Rus A, et al. Muscle& Nerve 2006;34:13544. 5.
Hammond SM, Wood MJ. Curr Opin Mol Ther 2010;12:47886.
2
Responsiveness of 6MWD to dystrophin restoration
-14 meters
- 44.1 meters
Minimal clinically importantdifference (MCID) in 6MWD in DMD has
been calculated to be 30 meters (McDonald et al 2013)
MCID definitionMCID for 6MWD in DMD Reference
a. Baseline SD (1 r) 28.5 m McDonald 2013;
Wyrwich 1999
b. Baseline SD/3 31.7 m McDonald 2013;
Yost 2005
3
Decline in 6MWD predicts loss of ambulation over 2 years
Percent ambulatory over 2 years
80 60 40 20 0
-30m -30m
-30m
-30m
-30m
-30m
7 Baseline 6MWD > 350 m N=42, N=40, N=36
Excludes n=1, n=3, and n=7 with loss of ambulation by
Age > 7 Baseline 6MWD > 350 m N=43
Includesthose with
Age > 7 Baseline 6MWD < 350 m N=22, N=12, N=11
Excludes n=3, n=13, and n=14 with loss of ambulation by
Age > 7 Baseline 6MWD < 350 m N=25
Includes those with loss of ambulation
Effect of Baseline 6MWD and Loss of Ambulation
(Data Courtesy of Eugenio Mercuri)
Time from baseline
100
48-week 2-year 3-year 75 study design? Follow-up? Follow-up?
aseline 50
b 25 0 from 0 1 yr 1.5 2 yr 2.5 3 yr -25 WD -50
6M -75
in
-100 nge -125 Cha -150 -175
-200
-225
Age > 7 Baseline 6MWD > 350 m N=42,N=40, N=36
Excludes n=1, n=3, and n=7 with loss of ambulation by
1, 2, and 3 yrs respectively
Age > 7 Baseline 6MWD > 350 m N=43
Includesthose with loss of ambulation
Age > 7 Baseline 6MWD < 350 m N=22, N=12, N=11
Excludes n=3, n=13, and n=14 with loss of ambulation by
1, 2, and 3 yrs respectively
Age > 7 Baseline 6MWD < 350 m N=25
Includesthose with loss of ambulation
(Data Courtesy of Professor Eugenio Mercuri)
DMD114673 vs. Natural History
both including andexcluding patients who lost ambulation
=+33 m
=-25 m
DMD114673 Drisapersen 6 mg/kg (n=8)
Baseline 6MWD= 417 m Excludes n=2 with loss of ambulation
, ,
DMD114673 Drisapersen 6 mg/kg (n=10)
Baseline 6MWD = 386 m Including 2 patients with lost
ambulation
Age > 7 Baseline 6MWD > 350 m N=42, N=40, N=36
Excludes n=1, n=3, and n=7 with loss of ambulation by
1, 2, and 3 yrs respectively
Age > 7 Baseline6MWD > 350 m N=43
Includes those with loss of ambulation
Natural history data provided by Professor Eugenio Mercuri
(Catholic University Policlinico Gemelli, Rome, Italy).Note: Direct
comparisons between extension drisapersen from DMD114673 and the
natural history data cannot be made. They are presented together
for illustrative purposes only.
26
Safety:
Drisapersen was generally well tolerated
Drisapersen clinical trial program: key safety data
Drisapersen is generally well tolerated, with an adverse event
(AE) profile consistent with that described previously forthis
class of molecule
59 serious AEs reported on drisapersen, most considered
unrelated : 15/59 serious AEswere considered related or possibly
related to drisapersen
12 of >300 subjects have withdrawn permanentlyfrom treatment
owing to AEs
Most commonly reported AEs include injection-site reactions and
renalabnormalities (including subclinical proteinuria)
Some cases of (moderate to severe) thrombocytopaenia havebeen
reported
AEs of special interest, n (%):
Any AE of special Injection-site
Study Treatment N Renal abnormalities Inflammation Hepatic
Thrombocytes interest reactions*
Placebo 18 13 (72%)6 (33%)7 (39%)9 (50%)1 (6%)0
DMD114117
Drisapersen
18 16 (89%)14 (78%)13 (72%)10 (56%)2 (11%)0 6 mg/kg/week
Placebo 16 9 (56%)5 (31%)5 (31%)1 (6%)1 (6%)0
DMD114876
Drisapersen
18 16 (89%)13 (72%)5(28%)5 (28%)1 (6%)0 6 mg/kg/week
Placebo 61 37 (61%)10 (16%)20 (33%)16(26%)0 0
DMD114044
Drisapersen
125 114 (91%)97 (78%)80(64%)33 (26%)7 (6%)0 6 mg/kg/week
*Includes discolouration, erythema, rash, induration;Includes
proteinuria, red blood cells in urine; Two subjects in DMD114044
receiving drisapersen 6 mg/kg/week had severe AEs reported by the
investigator as drug-related (glomerulonephritis, intracranial
venous sinus thrombosis and spinalpain). No severe AEs were
reported in the placebo group.
28
Conclusions
Comprehensive clinical trial program(>300 subjects) has been
conducted to assess safety and efficacy of drisapersen in DMD,
comprising both placebo-controlled and OLE studies The clinical
programme efficacy data suggest: benefit with drisapersen versus
placebo in boys with lesssevere disease clinically meaningful
benefit after longer duration of drisapersen treatment in boys who
are, on average, more severely affected
Totality of the data warrant a filing for Accelerated Approval
with the FDA and Conditional approval with the EMA
29
Conclusions
Prosensa and now Biomarin areleveraging what they have learned
from natural history studies to design confirmatory studies of
drisapersen in DMD characterized by
a) choice of the correct dose based on phase 2 studies; b)
longer trial duration based on our experience with the multiple
extension studies; and c) an emerging natural history
comparisoncohort
Drisapersen was generally well tolerated
AEs include sub-clinical proteinuria, local injection-site
reactions and thrombocytopenia Addressed by phamacovigilenceand
emerging dosing regimes (Intermittent dosing after loading; IV
route of administration) Overall safety profile is consistent with
that described previously for this class of molecule
30
Glenn Pierce, M.D.
Former Chief Medical Officer,Senior Vice President of Biogen
Idec Hemophilia Therapeutic Area
BIOMARIN ANALYST AND INVESTOR DAY 2014
BioMarin ANALYST DAY 2014 Whats New Today? Drisapersen Potential
near-term registration opportunity in large market with unmet need
Seamless fit within BioMarinsclinical, regulatory and commercial
expertise BMN 111 for Achondroplasia First 3 cohorts enrolled
Leveraging the natural history study to inform our understanding of
our patients and analytic approaches BMN 190 for CLN2, Late
InfantileForm of Batten Disease Enrollment completion imminent
Current study exhibiting excellent safety profile to date BMN 270
for Hemophilia A Launching Phase 1 study 1H15 on track two years
after licensing Expandedpre-clinical proof of concept to include
real world (clotting) assays
Whats New Today? PEG PAL for PKU Phe lowering in patients from
enriched study at 26 weeks is robust at ~60% Enhanced strategies in
place to facilitate commercialization Pivotal data now expected
1Q16 BMN 701 for Late-onset Pompe Disease Improved manufacturing
process with better purity, potency and COGS Modifying program to
leverage to be commercialized process Proof ofconcept in 20
patients of switch study; enrollment 1Q15/results 4Q15 Pivotal
study resumes 4Q15 Talazoparib for mBRCA BC Enrolling more trials,
including talazoparib in combination, neoadjuvant, etc. BMN 250 for
MPS IIIB (Sanfilippo Bsyndrome) Launching natural history study
with patient accrual expected 2015 Phase 1 study in MPS IIIB
patients
Financial Outlook Detailed financial guidance to be provided in
February 2015 with year-end release Consistent with past practice
Will allow for Prosensa budgetexercise 2015 Revenues: Generally
comfortable with consensus estimates 2015 Operating Expenses:
Consensus R&D and SG&A expenses without Prosensa
approximately 5% to 10% too low GAAP Operating expenses include
substantialnon cash expenses 2014 non GAAP loss guidance: $50
million to $65 million 2015 non GAAP loss to be
N%](7]Q@;&$`891B*&*\8U1CZ&2`9M11EK&9$9MQG=&@0:*AI1&GZ1\3'SX?:1^4'[\?ZB`5($$@M;""8(,0@\"$Q6LMMO'('+3OL3:I(S[^E6:!V"BBD9@BEF.%`R2>U`A:*JV%_%J5LMQ;A_*8G:77M;N'J/:K5&PVK.S"BBB@04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1165K=I>W"6\NG28GMMY1)Y;,560=U--*['%7=BK.0/&ML3T%B_P#Z%6,NOF_\RXDUY=/.X^5;K%N`M`Z;CCG-;=C97UQK!U+488K./9&I)QT!]A5W1M=CDT:WN-4N88I69D+,P4,5.,BI]$L)[".]$X4&6MY>5=IS\IZ5'HFC_9M)CMM0@ADD21V`(#@98GO2;3N1.4'=>AJP7$-U$);>5)M8ST9#D&L.V)'B[52H!;[-'@$XR:FU*QO(;BSN=(6/;;[@UKNV(X/?CC-1VFEMWLTNI7E[LM[B[C$2)$V[RP`0#GN:E628HJ*3=]_\S(O-1N;>VDGF\111WZY8M6D*JZ`]E]?QK1DU.]U*33K*TE%K)N:T?*:RY/*_R'RS:GMH5K?375P+VUBBWQ2.`K[\XVD#J/>J6H'7--T1M1_M+S)653)&8UVQY(^[].GM-7FT[4M76[&ILMM!+#Y26\;[P#G.\GUK+UT:V/#DUO=Q6Z0PJH>=),F4`@#"M]NV:4;76P0LY):7OK_7^1MP7UP_B3[*TF8/L:R[?>BYL]0@U2WU/3XHK@&W$,D3OL/J"#3+;1;RXNM6?4S$%OH5M0>4W=UDN555+;3&_M(R?7%6KG5Y1>26EA9/=RQ`&4APBIGH,GO[4`:M-61')"LK$=X^E3>&;:.'3$=;+[*[JNX[@3+Q][\YC$D+_>4DC-9H\16\=O>/=1M!-:MM>$G+-Z;?7-23ZR\,M-J/LVK6ER%WJI8,KMKW((]*J'Q#-)')I.*)'$IH`V**Q_^$AA-A%];=%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110M`4444`%%%%`!1110!CRWMPOBBWLU?_1WMFD9&+J=)K[3+R5Y)[:3*LY))4_Y_6M/6K\:;I5Q/`K(UD?V7XAL=4'$4Q\B;^A_P`^E)XBSJ>L:?I"'Y-WG38]!_\`6S^=`!86MKIIFF/?:I-!/)+YN&DYDST3GVQQ[UT5S=P6HTT:@_NWPP^8.=9G"*)"MISAL#.?>N7OHTF\!V]Q*BO,B*JN1RHW8X/TKJ].MH;:SB$$21AE#$*,9..M`M%NJNH7J:=8S74@RL:YQZGL*M5@>,59O#TVWH&4GZ9H`JV6F7VN0+>ZG?SPI*M-TF!3Y[JM"V*>?,D6\[5WMC)]*`,74IY5\4Z3$DKB-EI.!7)0LS?#N;WZT`;4FM:;%`)GO81&6*AMW4CJ*M6]S#=1"6WE26,]&0MY%*[NQMQMMI81,(QT4^WZT`;M,FL:=%"TSWD(C5MA;=_%Z?6G?VK8_9/M?VN+[/T\S=QGT^M7&F-;Q[UAN`[G(&!QS46IZ??6VK+JVEHDSE/+F@8XWCU!_P`]*Z"BM@#FTAU;6-1MIKR`V%K;MO\L29:0^^.U,^QZIH=_6=PV\Q;MK(WM73MT4`8-F-:OM1CN;Q?L-IB!6#&0_[5;U%%`#I]RGBZXOFCQ;/"$5\CDX';M\*WJ**`,?Q-97&H:.\%K'YDI=2%R!T/O5V[LEOM-DM)>!)'M)'8^M6Z*`.7MM9M?TJW6S;3EO5C&V.9)0..V:O&EO;VYW16ZGMNFHH`Q+NQN)/%%C>)'FWBA97?(X)SV_&BSL;B+Q/?WCQXMY8U5&R.2,=JVZ*M`,3PW8W%A;W:W,>QI+AG7D'(..>*6UL;B/Q3>WCQXMY(557R.2,=OPK:HH`YM[3-(EV:Q#>1[([N9BIR#E3GFJ]J^O:1;"Q73TO%C^6*99`!CMD5U-%`')S>'M;^;09(I)Q+?23"=E9CLS_='YU8,VNZA;&S&GQ6"LNQYFEMIJN@W=P=/MEO;*=]XCW[60FNHHH`PK%=9O=16ZO1]BM44A;96#%SZM2V.G3IMKVJSSQ8M[A5"'(^;C!K([VUCN8+2Q,V`*FTIX/^$NA>WM3:6TDM+"%2NW>`/O8]\&@"PL%WJWB#4[-KZXAM8F#$1M@YQP`>PZFK+_OL4?:K?_GO%_WV*`)J*A^U6_\`SWB_[[%'VJW_`.>\M7_?8HL!-14/VJW_Y[Q?]]BC[5;_\]XO^^Q18":BH?M=L.MQ%_P!]BD^V6W_/MQ%_WV*+`3T5!]LMO^?B+_OL4?;+;_GXB_P"^Q3L!/14'VRV_Y^(O^^Q1]LMOM^?B+_OL46`GHJ#[9;?\`/Q%_WV*/MEM_S\1?]]BBP$]%0?;+;_GXB_[[%'VRMV_Y^(O\`OL46`GHJ#[9;?\_$/_?8H^V6W_/Q#_WV*+`3T5!]LMO^?B'_`+[%M'VRV_P"?B'_OL46`GHJ#[9;?\_$/_?8H^V6W_/Q#_P!]BBP$]%0?;+;_`)^(M?^^Q1]LMO^?B+_OL46"Y/14'VRV_Y^(O^^Q1]LMO^?B+_OL46"Y/14'VRV_YM^(O^^Q1]LMO^?B+_`+[%%@N3T5!]LMO^?B+_`+[%'VRV_P"?B+_OL46"Y/14M'VRV_P"?B+_OL4OVNV_Y^(O^^Q2L%R:BH?M=O_SWB_[[%'VNW_Y[Q?\`?8HLM%R:BH?M=O_SWB_[[%'VNW_Y[Q?\`?8HL%R:BH?M=O_SWB_[[%'VJW/2>+_OLM46"Y-147VF#_`)[1_P#?0H^TP?\`/:/_`+Z%%@):*B^TP?\`/:/_`+Z%'VF#M_GM'_P!]"BP$M%1?:8/^>T?_`'T*/M,'_/:/_OH46`EHJ+[3!_SVC_[[%)]JMM_\`GO%_WV*+`345#]KM_P#GO%_WV*47,!Z31GZ.*`L2T5'Y\7_/5/\`OH4>M?%_SU3_OH4#L245#]JM_^>\7_?8H^UV__/>+_OL4!9DU%0_:[?\`Y[Q?]]BCM[7;_`//>+_OL4!9DU%0_:[?_`)[Q?]]BC[7;_P#/>+_OL4!9DU%0_:[?_GO%M_P!]BC[7;_\`/>+_`+[%`69-14'VRV_Y^(?^^Q1]LMO^?B'_`+[%`69/14'VMRV_Y^(?^^Q1]LMO^?B'_`+[%`69/14'VRV_Y^(?^^Q1]LMO^?B'_`+[%`69/M14'VRV_Y^(?^^Q1]LMO^?B'_`+[%`69/14'VRV_Y^(?^^Q1]LMO^?B'_`+[%M`69/14'VRV_Y^(?^^Q1]LMO^?B'_`+[%`69/14(NH#TGB_[[%+]I@_Y[1_\`M?8H"S):*B^TP?\]H_P#OL4?:8/\`GM'_`-]B@+,EHJ+[3!_SVC_[[%'VF#_GMM'_WV*`LR6BHOM,'_/:/_OL4GVJ#_GM'_P!]B@+,FHJ'[5!_SWC_`.^Q1]J@M_P">\?\`WV*`LR:BH?M4'_/>/_OL4?:H/^>\?_?8H"S)J*A^U0?\]X_^^A1]MKMQUGB_[[%`\?\`WV*7[3!_SVC_M`.^Q1=!9DM%1?:8/^>T?_?8H^TP?\]H_^^Q1=!9DM%1?:8/^>T?_`'V*/M,'M_/:/_OL47069+147VF#_`)[1_P#?8H^TP'I-'_WT*+H+,EHJ/SHO^>B?]]"CMSHO^>B?]]"BZ"S)**C\Z+_GHG_?0H\Z+_GHG_?0HN@LR2BH_.B_YZ)_WT*/.MB_YZ)_WT*+H+,DHJ/SHO^>B?]]"CSHO^>B?]]"BZ"S/'\#THP/2BBO9,`P/2MC`]***`#`]*,#THHH`,#THP/2BB@"C=`>=T'2H=H]!4]S_KOPJ&K6Q#$VCT%M&T>@I:*8A-H]!1M'H*6B@!-H]!1M'H*6B@!-H]!2,HQT%.I&Z4`1[1Z"C:/0M4M%`A-H]!1M'H*6B@!-H]!1M'H*6B@`51GH*DVCT%,7K4E!E/E&!Z4M%`"8'I4$P&_H*L5!-]^DSJPG\0AP/05HZ2!YC\=JSJTM)_UCM_2LY_">JMS5P/2DP/2EHKF+.>E`\Y^!UIFT>@J27_7/]:96IT(3:/04;1Z"EMHH`3:/04;1Z"EHH`3:/04$#'04M!Z4`9Y49/`ZTFT>@IQZGZTE(0FT>@I^!@M@HHH/4#`]!1@>@HHH`,#T%5[D#Y^\M@IYZ4VO)-A-H]!1M'H*6B@!-H]!1M'H*6B@!-H]!2[1Z"BB@#1C`M\M>!TI^!Z"FQ_P"K7Z4ZN9G*&!Z"C`]!112`,#T%&!Z"BB@`P/05+;`>>O%1M5-;?Z]:"9;,UL#THP/2BBM#B#`]*,#THHH`,#THP/2BB@`P/2C`]***`.9HHMHK[$^3"BBB@`HHHH`****`*5S_KOPJ&IKG_7?A4-6MB&%%%%,04444`%%%%`M!2-TI:1NE`#****!!1110`4444`*O6I*C7K4E!E/H%%%%`!5>YM^\M%%0F/":0)MN@G/">4)^PH1"B@2!Q(F$D429!*$$J,2PQ+C$P,3M(Q-#$V,[email protected]$\43Y10&%"!6;%;T5X!8#M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9M11EK&9$9MQG=&@0:*AI1&GZ1\3'SX?:1^4'[\?ZB`5($$@M;""8(,0@\"$JO?:3%M3*B(G`RV:8)%R=H*@]AM4H.4WA@,\C%?/&F@@;`X!R#WIV^,KAAWX'?-,=&7!+@YZ4T;@,)@Y/4T#%ECMCF&UUQ3$L[=>=@3Q4:R?*H(YJ4'/2HM8^BA44XW3(IE+)QUJ71;ADM]0A*@@QCD]N:;)]T\]MJS(]0:U2XBC`(F&TD]JWI+FT/'S+E331T/AFZ_TN2.50S$9A?WBX!X'3FD8S(F/,SV':LPYA#:CN>>XH^SG^]SC]*0)(G'J=-$?W*#VJPC#;Q6P.IA"\@]:E)]:*B:,B)ZKR=MZG:H9.E0A'HNG?\`(-M/^N2_RJ#6;X6.GRR9P^W"CWJ?3O\`D&VG_7%?Y5RWMC"0(B]68X`KD]$B:MU,C-)NWL36W?:>-9T]K42F(LP.[&>E=#,DM3I;65)XEEB8.C#*L.AJVF"W)XMZUG:5:+96Y]Z`6YTT`(11[4^;Y8P!]]CA?:F0MMP,5*PS4V,U'*N8W'?!J7L-'$RM2;YY&[DUNZ?B.P5CWYKGW0B1_K6B]T(K6.,'HMM:;?#]Q>0-_L[L&KZ]"4PP]0LY99)3YB%B6PK``?3BMK1-M.-C#%-!>78W#)C,F5/X8KGG@G]EEJJGN=IOD'\!IAGVGE2*Q;W7;FTB7RD1YM7.U%(X_&JQU/7RH;RK1B>WE'_&L/JM1&BDGL=1'=1,,,PI)X$G'!_$5Q-[XHMUJP3>T%EQU_='_&K.E>,KN]C?S4@5U&1M4_XT?5JA/-9FAJD:M]KL=[^&1.>I4\UV)\6:F!PMT8_`_P"-(WB_4BNUQ`X]'3-+VT1JC,YJYDM[S3(EAMLW8;+2`]1Z8K&DC=!70FE$Y9IW-2Y8BV_=G#'@5S$BLCE7&&!YMK?28W+!\8C7[OO5;4;831F5?OJ/SK&H[LJ,=#$:H).E2DU%(>#62`]$TYP-/MM%S_`,L4_E7`>(]8LY?M-OYJ^:LQ[_G76V[E4M"S$*(4QCZ5Q6I>$;>:?5'CMDE,Z+YT49Z.#W_/-=,*O*S)JYEP:A;1L1O!7U'K6M::]8PH=\A+>PS7-VMF4MARZ8SV]*U-.TF.ZEP[;5]JN5=FD*"9L'QA91K\L,SX]L5&OCVV\T`VDBIW.[MD5K6>DZ0B")HHW8C^+DUCWOAFTCUKY%Q;+$974U*JR9;HI;%K7]8MY-+5H\2MIC.3CN:72M-T6[0?YBHS*FM>&IVDY"WS'IY!_F*J=237IX>?+31GRDQ3NM&*U,AA6D([4\U0O[X6PV+_`*PC\JF326HU'F=DIY5Y,I[,:MSS,96/H*O7A+S,Q.2>IHTW2WNY!QA`?F;TKE6IVWLM2QI&EF[?S901"OZUU*MQA5"J,`:;`ZGS'\]SL`P`/O4OSD[MJM_7=6%/I]\]M)'YGDMY4=RVQ^,]0Q.D8&U,]0*DIKJ0@[CFHWE5.3FJ\MSLLS(/O'@?6MDL$+H99"68\`FLE%)79JY-NR)?M2'%LY'7BK354OO^/5_PJX;HB?PLR]VM!SR32M(74+V%1]Z=@G`%=AP$T.1!*V#CIFHP=H#>]*DLBPO&&(C;&X>M!VF,M?-DB@9N6;!XUSQ6G%;*_/%8FFGA_#W3(6M'U&129G)16S]U1U_.N^B1$Y50#T-35=?O);*>TCNIXY(EFM3:679C./\]:AGN&T+QAJ%[=6EU-;7UO$L,L$+2[63(*$#IG.?2@#6NO$UC;*MKA+J=&B$Q:"W=PJ'H20..GUI]UXETJTL[6[FNAY%VI,#*I._C.``.OMZUA:KMJ&HSZBL,O]I6-I+:J\$=K`'>24YRCM@A2...![U3TW3;M+#P5'+:2@VTCF8,MA_=_*V"?3G%`'17'BW3+;[.)3XN`%NE+P%5+>8``>,=2E0VT42RO%$D4;.\K*XL;:R:TD:",R&-R0V\@)I"6;'SXX%=#X5U#^T-#@9FS)&/+?ZBAQLK@X6MC:C;PRCJC/R/KZ4W%IV$I)JYJ455_M"T^P_;?M,7V7&[MS@XVX]ZDM5F0W$:AGC!^90>A(JG=^M(M(L;G[-=ZC;PS?W&;]IOH(O)8+(&2(PA?'0,PY-',@Y65[FQAU'Q]M8B_A20QZ=YA1AE=^['3OC)J6WMH;'X@S+:0K$LNG;W1!@,P?&F0^%[IX;6&MW>TC\R"2-0K(R],&M[5=+M]8T^6RNU)BD'53@J1T(/J*P#X0O+L1V^JZ[(?$D]S;QS.+H(OF*&VC&>,_YMXK(T=]2NKC4KV+P_;:E+)=2(\T\Z@J`VVW']A>&)=2BMEE8M=W+(!(>7Y3LJ!U=?WFN+6&XEO$,D\DBAF=B3GFK^D>&ETK4KMJ]-Y-=27,:I(90"6(ZMGW].U4CX1N[7S8=)URXL;&5BQMP@?9GKM8\BBZVN%MGO8S=3TS38&\,6UJ4N[=;SR=[D2$KR=A/H#VKNDC2*-8XU5$4855&`!Z"N>NM_",+:586>G7+VZEN+N^4B>ZD'S-D$#`[`9Z5;=B$KF'IUK#IGPZ%]:01K>"S:03!1OW$T60)#^>*[6#088[O5YI7,T>I;1)&1@*`MNW&?>L@>$-12V^P1^(KE=,QL\GREWA/[N_TQQ34D'*SI--G@N=.MIK1BUN\:MF,GKMQQGWKFM+M+?5/%VN7%_&D\MJT7/C4VU^XWB"/'DQGLI7'..].UF]G\0^%M(U#[4T+_:TAD2(#:7MW8WCZ8R/K3Y-=0Y]-#TBBJUA;26EE%!-`[6('&]CCN>U7=.UHZEH>OV$M['J/V2!BETHQYJ,AQD>H((I\C0N9+G!9"W1E/]*.4.8[*BN)9-7UCQ5J^GQ:I/9V$'MEL3%C>"5X53VSR3]*GL+S4-/N-8T>^O&NI+>V-Q;7###E"".?.*`.D,B`@%U!/3GK1YB!BN]/6@M#>O=7M+#R_.9B)(Y)%*#%.])DC0OEAM`^4]U*=#P>*U]0AOXM=AOK.S^TH+1X2/-5-K%E(SGMQVMH`MIKFGRW]M9QSAYKF'SXB@`]@OO3]/34K==7:73)`US,9HE$R$G*JN.O!X)H`OS:]:M16,-Z([F2VEB\X21P,P5&;QHS++;QOM>)#8I'*7!96C;,F#VX_.IK+0[R#7[6XDL8L0W%S))>>8-TJR!M@QUXR!STQQM0!M77B"QL[N6WG,RF':99!$QCCW=-S`8%3P:M:7.I76GQR$W-L%:12I`P1D8M/0]1^=8NHZ=J4MYK45O:JT6I11Q+.T@"QC:58D=3UXQ4%UX>U$75W-9%4>25M8ED9N3`T2(Y^H*@CZ4`:B>*M-FCC>W-Q/YDCQH(H&8DIC=P!TY'-6'U_3DAMM)OM&Y+MPD)52S/G)."=Q.RE1I429YZ?6H+2^AO6N%@)/D2>4Y(XS@'CU&&%%4'!/N`>.*K6FA-;?V-NF5AI]L\#87&\LJC(]/N_K6E9DGAVZ6TL$MM;J%9K>R:R=I(RRLK!06`R.>'7N--TJ!)E\_3U4`MN"O\FP_=((]>M`M%V3Q!I43HK7L67B\]"=W';@\TC>(])2"*=KZ,12YV,+-513M0Y?>MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HMHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"D/(I:*`,=M!5X;J)[ZMZ*W3;I/NC)X'IW``Q6E:P&WA$9E:7'0L`,#TX`%344[C;;"BBBD(****`"BBMB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HMHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBLB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_`end
GRAPHIC21g836571img26.jpgGRAPHIC
begin 644
g836571img26.jpgM_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&ENM;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@ML![\'T@?EM!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".0F/":0)MN@G/">4)^PH1"B@2!Q(F$D429!*$$J,2PQ+C$P,3M(Q-#$V,[email protected]$\43Y10&%"!6;%;T5X!8#M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9M11EK&9$9MQG=&@0:*AI1&GZ1\3'SX?:1^4'[\?ZB`5($$@M;""8(,0@\"$HIIMM;#3:V,_3-$T_1U86-LL1;[S=6/U)J34=+LM5A$5];I,@Y&>J_0]15RBB[W"M[OBV.C1R1V$1C60M@MEB&/4+F.Q=MS6P/'T^E=*]W"G60?A5=M3B!(56:N>>-MHTMYHN,9]$6K>".V@2&)=J(H51Z`5)GFLTZA.^?*AJ)EU*AXP:L^`M=GOHI=/NW:1X%#1NW)*]""?;BMAQ5KH;@K(=+2_C625-,RP1P`2[=3CM^%6988ITV31)*O7:ZAA^M%AV.:CT^&'3+6--6LQ+%-&CZ;&4$?E0DM,4'5Y;Y;80GYM0@@$:G/M7"'GZ'B@#?LM1L]2C:2QNH;E%.UC$X8`_A4ZQHC,RHJLYRQ`P6/3FN2T"]MXM-3U6>>^M+I-D.Z]@`CB'+!8\9(W#.>I^\*U/$3W&=+@MKN6U-Q=B)WBQNV['M)'(/I0!N5#@KDTN=5^S300W.I3M;7DL'F6\3R/QIOB%K%%FU9R+U3^Y:]$:29WC.`IVYQZ=J`.IO-4L-.,8O;MR"W,AP@ED"[OIFK0((!!R#WKD_$UY97-H6@UC3;=I;=OFEC60S(>,*V?7(X!MY[5N:1=0/8V=NJ^1,+6.3[,S9>-SL$\]>DLA+L/IMGI^%`%BWTI-0\-VMCK4(G8P()EDY.X*,G/KGO7,3?"309)"T=(NQI)7W'&"=&UO4UU&^AE:X`4?M+(0#CID5T5%`$H(P:Q=!\'Z3X;N)I].CD625=C%Y"W&HH`QM>\+:5XCC5=1M]SIPDJ':Z_CZ>QKF4^$>A+)N:XOF7^[O4?KMKOZ*M`*&CZ-9:%8+9:=$8X02V"Q))/4DFLS2?!.C:+JC:C912K%/^VWM'\MU>L:UHEGK]C]BU!7:'>'PC%3D?3ZTS1/#^G^'K5K;383&CMO8LQ8L?\-Z=XDMXH=2C9UB;Z`N@7NE7UFT-JT,LLT>U#_#A3W.#FNTHH`\ST9G\,V?]E:SX5GOI(78M175M:K*)5)R,G\:Z"^TR3Q%X*O+6+3/[+FG!:.WU?QA8:-K5GI=RLIEN=OSJ!MCRUK0H`***K:AU1M:T.SU%XQ$UPFXH#D#DCK^%:=`!1110M`445AWNNO:>*=,T9`L7V.[>V&UL[M@O>@#=HHHH`****`"BBB@`HHHH`****`"BBB@`J.;=Y$FS.[:'=+AA\/^=:A`!;C.S5R,R_!2%@2&$@P?\`MM6AXMT"RT3PS#JUD)!JD$T4GVQG)ED8MD`[CWSGI0!Z+)+'$A>5U11U9C@4B3128\N1&SS\K`UP?B>XT_P#X2[3E\1$-MI7V-I$C.602[L;G4=L42"-BI=1R5R.QQ@T)I]MH'Q&TZWTJ,6UM>VDGG0IPC%'6M)N?#_`(8U+2WCG5+@L@6-XCP=V"X5"8P[?+NQQG';-0Z5+>MIU9FI:'XGU*VN--FU2P:PGRK2F!O."M$],`[VBV\$"P^3>1DCY?X@R\Y]JJ6G@E&T35;/M4[D37.J2F::6)-JH_4;1['\ZZVB@#E;?3_%\44=JVJZ:84`7[1Y#&4@>H)VYMJ?Q!X?N[[4+'5=*NH[;4K,,H,JEDD0]5;'/_`.NNCHH`Y&W\,:K+XDL-EK&NH:B)6FB\PVMH[]H58GCV)/Z5Z#5>RLK;3K5+6SA2""/[JM(,`.@S2Z+J%M''-'V@\2ZMJDLJM20W\21B+'(VC!R:WJ*`..L?#_B+08FL=&U"PDT\.6B%W&Y>($YP-IY_&KVN^M'[W7/"W]ESWL;7;%&>P)'RGM-0:[X=N[S4++5=)NX[;4K13*I:.1#U5@.:Z2B@#`M](U.^M;Z'Q#>03QW4M7E""U0JD8YR03R3S^E4+/2/%FFVD>GVNJ:;):Q#9'/-"YE51T&`:[J(UN32=/L(I9TA2;S))"J*#G.>/8`?7VJQJ%YKTMLK,PQ*#F:5:4J2QSM\AP/N^I_2M>[UB^AFL]/BMK=M3G0R.#*?*B4'&23C/M6;J^@GME@FCB8!T*G((R1D2\-\)9(Q(&,"`2?7ITJ="M3/)B2X\:O/`L\2B-GB8D!P(NF11J5]JM,'-.N+2PU"&[C,9FO)G49!RC'M@TG8:N0V6N:MJ>V\LM,A?3&DVH6FVRNN/?.#TQ22Z5JOV?Q.+0&&>M[F#6[!P"PV@'![="*;2%J7HM9U&VUFSL-4MK55O`WEO;REMK*,E6!`[=ZQHWMABTKQA)11\JG)Z`\^]&KPWNHW.G75YI-S-8JKB:Q612P?/RL0"`PQM[\4K(=V2OKE_>Z%K`6WBAO['?')ME.W&W.]3C._6H7M=3OO`TFEMG3)H+J&.*)5=U_>%2,D[,7G2-,Y6.).@S@M$DD]JAB\23K8ZM]LLUAU#34WO$'RCC&5(..AQ3+VWO\`3/$`U:ULGOH)K98)MHHV`="IR",X!'-5SI6HWMKX@OI[;R;G4(/)@MMX+!54@;CTR2:$D.['GQ-J4M,=E?76F1Q:9=.B!O-S*N[HQ&,8SVSFNKKF-5TR\N/"VG6D4):XB:V+IDMZJZ0Z//I]P#%=7L2%TP0Z-G(H28-HZ"BD)"@DDM`#J37(Z_XOLCIDPTC4D^UK(@&T=1O`;&1@\>E"3>P-I;G7T5G7^NZ=IDHBN[MD)*5W[%5G.WU(`.!5#6O%5IINCQ:A;/'ZG9:AK2M;7=-33UOVND%JS;5*(8(;:,16\211CHJ*%`_`4^87*7NDS?#F.VMMY(6D:!(XH%(W^=QP%ZYW9K0O)5M/%/A][V5(\6DRN[L`-V%SR:Z%-*L([LWM:65NMR>LHC`;\ZDN["TOT5+RVAN%4[E$J!@#^-',@Y6:O+.V$&UM[;/D0119`4[$"\#MH./2E=6L.SO;&"?1[>31=S>M?K]MXK?]ZB7#J)(UEP,=P,]0.:ZHV5L;7[*;>+[-MC;Y6P;F.E,_LZR%F+/[)!]E''D^6-GY=*%*P.+9R=[IUQY6N78U2"\O9+`MQ-%;QA"!R02`3SC(JIKM_I$O@G3H;:6W:3]SY*+@LA!&[CMWS7I(J6*QM88&@BMH8X6SNC6,!3GU'2A22ML#BV[N=.AEU"V%M=,#YD0.0ISZU+BTKLI23T+MM%)@SLP%SP"U-QULM)2NKG145YSXB\4W^H>%++4-.B>UCEEVRR)+ADC>)9[G59]*U2WAM[N*/S5:&7?&ZM?7M6IJ6L6NF:;65K%821&1989]Y3V8>O^%9M;^-[Y[235;;386TJ-]I+3XF90>`C#/+=>N.:V-5L]6L?&1'$ZOH>MHW/A[P[:PVY::UEA:9=P^0!I$]LS8$@8Y.#]:[33-)L]'@>&QB,JG4UT)4--3DO#&GIM%J$DZ^&%TA5C($K2AF8DCC`[4OCS2K[5=/LET^W,\D5R)&4,!P`?6NLHJ>9WMN5RZ6.&U.R\0^+1!97EA'I>GK('E8S"1WQV`%7H=)O;?QI>7\5L#:?81%$2PM`9AC"^HZ5U=%/G>PS>)+&]LM#DT7RWW7;^"X64*0I[-G_/6O3:*/:,7(C@M8T:_:#1?*TEGT^%2;C38M)L88\]H44_:,.1$%G"+>S@B6)80B!1&IR%XZ"IZ**S+"BBB@`HHHMH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"MBBB@`HHHH`:[K$C/(P5%&2Q.`!5+3-9T_6$D?3KI+A8SM;;G@_C5B\M8[ZSFMM9LF*9"C8.#@C%8OACPG;>&12>2M-6L)WN=#1112&9'MB/4Y])T^.XMPA=IXXSO&1AF`-3WNN:;ISO'>7:1.BARISG!.!@=^AZ5E^-O^M0+#_`-?D'_H8IJQ1R?$1V=%9H].!4D9*GS",BK25B&W*]$BMH;AM1B\JM;.PC)Z'!R`,C\:NW.JV-FD3W-U%$DP)C9CPP`R>?IS7,:3;6_D^+B(8\FYF0M_*.FS./IDFLV6:VBT7P7+?E/LRN"YDY4?)QGVSBGRH7,SM--US3M7:1;"Z69MX^67!4@>N"!Q[TVV\0Z7>745K;7B2S2J655!/`SGG''0]:R/M%O>^.[1["1)M?)LW%P\9!&"1L!(]^:@\*P$>"+AK1`+B7[00R]6?+`?R`IAX99)5N$"X)`3M*Y!&10DV#:1U5%8]GJ0BCU.:^U""6&UG8$HA7R5`'RMZD>M7IM1M;>.WDEF5M4N'5(B?XV;H!]:+!*8YMBPC*J6+D'!P`,G%%F%T:M%9T6N:;/ISZA'=HUK&]M9LS13GQEV:[2[L;6_B\N\MXKB/.=LB!@/SIR6EO'M;?9D@B6WQM\H(`N/3'2A2#E.3B(_M;P;_P!>DG_HI:S+O!\(^*,]/[2?/_?:M5Z!]F@#1,(8]T0Q&=HR@Z8'I339VK1R1FWA,3S;E&,@W'G('#8_"GM%JVH-,Z&PC2&PMXHI?.C2-563.=P`QG-]:'B*W\KP%"EL@2%$@+A5R`F06R.X[FNK%I;K;?9A!$+?&WMRM@VX],=*DV*$V;1LQC;CC'I1S!RG*BREOK_`$J>XUVQF$$OF0)#"%9_E.5!MW'C'\JV/$@)\-ZF`"3]FDX'^Z:GMM(TZSF,UK8VT,IZO'$JG\P*N$!@01D'JM#2;U&EH+RU;>%V#`;.+T@4[%O$9U3^[A2_'TS780MZEI%P+>.TGMI)&B)@6,@D+CG&.@Q6@MO"AD*1(IE.7(4#>??UJ&UTRQLF=K2MS@@9_O&.,*3]&KB0[88M01I'/11O;D^U;9O;:\\?V@MIMDF$=C(K,AR`=P.,^N/YUTGV.V-J;7[/%]G(P8M@VX^G2FV]A:6@C%O:PQ",$M)L0#:#UQ]:;E;.+B.3!9Y"3CCJ3TQ18'Y/`O/M\$G_`*+KLFTRQ>[^UM9P-FI:ZB*.]=B\:[5D)"XVCW-=?1"ZN--\37NL^;*T-MJ1AF7\F*-C)Q\H_7]:OV>MB.?2YZ)17ENMMYOA_P`'1SS.ML4I`E;S"N5^4$D_0FKVC,MAXU?3]!O9+G3VMRTJM)YB(^#CGZX_.CDTN/GU/M0\C.,C/I2UY+H:Z7/?30>([B]M-M349'_MCP2-[_-$F[YCSPO6J]F3MSGH=%>3ZA)I'_"5:^-;GND"L/(\EFZXYZG6NN^'\UU/X:1[JY^T'S&"$ONM95[!CZ]>*3A97&IW=CH;J_M;)H5NIXXFF?9&&.-[>@JP2!U(%K%\7%-5_Z]VI+,M*G:'3[BPLUGBLY3(]LB\,#@]!].?K4?P[5ETZ^W*1_IM)ZC'85M:UXABT*>`75K.UM(#F>-=P0CL153E+VVFHEL5=,\1Z-KLD4!18[I"M"D,Z`,K#^[]*Q?&UVCZ]I=GF._3]35?6+NT\4ZMIZ:'!M(URDH:2Y$94*O'4^U:WB^PNX;^PURQA,SVAQ+&HY*YSG]2/QIQBH33VO?0"*M^\1Z=>Z=+9/HNH^6R%57[+@*WD=ND@HP/05V?4O[QR_7/(]Y^VVO\`S\P_M]]BC[;:_\_,/_?8KP;`]!1@>@H^I?W@^N>1[S]MM?^?F'_OL4JW=NS!5GB9CMP`'&37@N!Z"M3PV!_P`)'IO'_+PG\ZF6#LF[E1Q=VE8][email protected]*Y+XA_\`M(NI_U\+_`":NMKDOB'_R+J?]?"_R:M:'\2)E6_AL\LHHHKVSR`HHHH`*.U%'M:@#W+1?^0+8?]>\?_H(J]5'1?^0+8?\`7O'_`.@BKU>!+=GMQV054U/_`)!=MY_UP?_T$U;JIJ?\`R"[S_K@__H)H6X/8\*[44=J*]\\0****`"BBB@#TOX;?M\@J\_P"N_P#[**[6N*^&W_(*O/\`KO\`^RBNUKQVM]K@Z*/8P[!M[21WG_"TK[_H%V/_`(]74^"?%EQXDN+Q)[2W@$*J08L\Y)ZY^E>-5Z+\)O\`MC\U3_KG'_,UG5IQC!M(N$VW9GJ5%%%.?%#_`)&B/_KV3^;5['7CGQ0_MY&B/_KV3^;5OA_C,ZGPG%T445Z!S!1110`5K^%?^1ITK_KY3^=9%:_A7_D:=M*_Z^4_G4R^%CCN?0%%%%>4=@5Q7Q0_Y%9/\`KY3^35VMFL?"C_D"WW_7S_[**[^N`^%'_(%OO^OGM_P!E%=_7FUOC9UP^%!111611X)XQ_P"1MU3_`*['^0K#K@HP/047J?S?@'LZ?8]S\'Z*VC6MS&UU!
